医学
维多利祖马布
癌胚抗原
嵌合抗原受体
不利影响
结直肠癌
细胞因子释放综合征
内科学
耐火材料(行星科学)
结肠炎
临床试验
胃肠病学
肿瘤科
免疫疗法
癌症
溃疡性结肠炎
疾病
物理
天体生物学
作者
Kexin Ye,Chaohui Yu,Zhe Shen
标识
DOI:10.1177/17588359241309825
摘要
Chimeric antigen receptor T (CAR T) cells have shown their potential in hematological malignancies and the treatment of solid tumors, especially in metastases. However, CAR T-cell therapy may carry risks of inducing severe adverse effects, which are recognized as immune-related adverse events. Here, we report two cases of severe colitis presented with refractory bloody diarrhea, which were induced by carcinoembryonic antigen (CEA)-directed CAR T therapy in the treatment of metastatic colorectal adenocarcinoma. These patients were treated as part of a clinical trial. The clinical trial was registered at ClinicalTrials.gov (NCT05396300), submitted, and started on May 25, 2022. Glucocorticoids combined with vedolizumab were used to control their gastrointestinal symptoms but the outcomes were unsatisfactory. This report highlights the potentially serious risks of anti-CEA CAR T therapy and provides management options.
科研通智能强力驱动
Strongly Powered by AbleSci AI